Nebivolol Teva

Nebivolol, the active ingredient in Nebivolol Teva, is a beta blocker presented as an oral tablet for oral use. It is indicated for the management of hypertension and chronic heart failure in adult patients.

GNH USA supplies Nebivolol Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol belongs to the beta‑blocker class and is used to control cardiovascular conditions.

Hypertension: lowers systolic and diastolic blood pressure, reducing cardiovascular risk. Chronic heart failure: improves left‑ventricular function and reduces symptoms of fluid overload. Left‑ventricular systolic dysfunction (NYHA II‑III): enhances cardiac output and exercise tolerance.

Nebivolol may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache - Dizziness - Fatigue - Bradycardia - Nausea

Serious or Rare Side Effects: - Severe bradycardia or heart block - Marked hypotension - Bronchospasm in susceptible patients - Allergic reactions such as rash or angioedema

Before prescribing Nebivolol, clinicians should consider several safety aspects.

Monitor blood pressure: ensure adequate control without excessive fall. Assess cardiac function: avoid in patients with severe bradycardia or advanced AV‑node disease. Use caution in asthma or chronic obstructive pulmonary disease: β‑blockade may exacerbate bronchospasm. Review concomitant beta‑blocker therapy: additive effects can cause profound bradycardia. Adjust in renal impairment: dose may need modification in severe dysfunction. Store at room temperature: keep in the original container, protect from moisture and light.

Nebivolol can interact with several drug classes; some combinations should be avoided while others require monitoring.

Major Interactions (Avoid): - Other beta‑blockers: additive bradycardia and hypotension. - Verapamil or diltiazem: increased risk of AV‑node block. - Potent CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): elevated nebivolol plasma concentrations.

Moderate Interactions (Monitor Closely): - Diuretics: watch for electrolyte disturbances and excessive blood‑pressure reduction. - ACE inhibitors or ARBs: monitor for additive hypotensive effect.